Introduction
Positron emission tomography (PET) is a noninvasive nuclear medicine imaging technique with clinical and research applications in diverse areas of medicine, notably in oncology, cardiology, neuroscience and in drug development.
1 Following administration of a radiolabeled bioactive molecule into a patient or research subject, PET can provide a quantitative time course of three-dimensional images stemming from molecular interactions in vivo. Among the commonly used PET radioisotopes, 18 F is the preferred radionuclide largely due to its suitable half-life (110 min) for synthesis and imaging.
2 Because of the importance of 18 F-containing radiotracers in clinical and research domains, much effort has been devoted to developing new strategies to introduce 18 F substituents into complex bioactive molecules.
3
Despite the recent advances, current methods for incorporating an 18 F atom at C sp 3 positions are still dominated by traditional nucleophilic substitution of no-carrier-added 18 F uoride with a precursor molecule, typically bearing a suitable leaving group such as an alkyl halide or sulfonate at the labeling site (Fig. 1a) .
1b One major drawback of this displacement approach is that the preparation of the precursor molecules usually requires multistep synthesis and the highly activated precursor are prone to degradation, for example through elimination of the leaving group. Accessibility of precursors, in fact, oen hinders the development of a radiotracer in PET imaging for research applications.
A potential solution to issues related to pre-functionalization of labeling precursors would be to develop methods to directly and selectively convert C-H bonds to C-18 F bonds, thus obviating the complex precursor synthesis. This is feasible given the rapid growth of direct aliphatic C-H 19 F uorination over the past three years (Fig. 1b) . In 2012, Lectka et al. and our group independently developed methods that can directly convert unactivated aliphatic C-H bonds to C-F bonds.
4 Whereas Lectka's system relies on radical-based chemistry between a copper(I) promoter and an electrophilic uorination reagent, Selectuor, 5 our method utilizes nucleophilic uorides from AgF/TBAF as the sole uorine source, in conjunction with a manganese porphyrin catalyst. Since then, a number of other elegant protocols have been reported that can selectively construct C sp 3 -F bonds by means of C-H activation. 6 Whereas most of these newly developed uorination methods utilize an electrophilic uorine source, such as Selectuor or NFSI, our Mn-based chemistry appears to be the only method that currently employs the uoride ion, making it particularly suitable for 18 F labeling methods. 
Results and discussion
We chose Boc-protected 1-amino-cyclopentane-carboxylic acid methyl ester (Boc-ACPC-OMe) as a lead substrate for direct C-H 18 F labeling. Fluorinated derivatives of this unnatural amino acid, 3-and 2-FACPC, target amino acid transporters and have shown uptake into brain tumors, but their preparation requires multi-step syntheses.
9 Aer extensive screening, we found that a manganese(III)pentauorophenyl porphyrin coordinated with a tosyl ligand, Mn(TPFPP)OTs, was the optimal catalyst. With Mn(TPFPP)OTs in conjunction with iodosylbenzene as the terminal oxidant, Boc-ACPC-OMe could be labeled efficiently with 18 F to form 3-uoro-Boc-ACPC-OMe (1) exclusively. As is illustrated in bonds were efficiently labeled with radiochemical conversions ranging from 12% to 67% (Scheme 1). Common functional groups, such as esters, amides and alcohols were well tolerated in this initial assessment. The labeling usually occurs at the least sterically hindered and most electron rich methylene or methine positions. For example, labeling of a series of substituted butyl benzoates (2-6) occurred mainly at the methylene positions remote from the electron-withdrawing benzoate group. In addition, substituted ve-membered ring compounds (7-10, 12-14) afforded C3 labeled uoride as the major products, probably due to a stereoelectronic effect. Notably, labeling of 1-phenylcyclohexanol (15) resulted in 18 F incorporation exclusively at the positions cis to the hydroxyl group, suggesting the involvement of a directive effect in the uorine transfer step, similar to that observed in the analogous Mn-19 F uorination reaction. 4b Moreover, this labeling protocol can be used to prepare radiolabeled drug precursors, which can (20), which targets the 5-HT neurotransmitter system, 11 was prepared via a two-step protocol in an overall 30% RCC. The specic activity of compound 2 was calculated to be 1.24 Ci mmol À1 (end of bombardment), which meets the imaging requirements for uorine-18 labeling reactions. In order to demonstrate the utility of this method for latestage radio-uorination, we applied the reaction conditions to a variety of bioactive molecules (Scheme 2).
18 F-labeled natural and unnatural amino acids are an important class of imaging agents for PET that target the increased rates of amino acid transport by many tumor cells. 12 We anticipated that a direct uorination method could signicantly accelerate the development of amino acid based PET tracers. Although direct uorination of leucine and valine have recently been achieved using electrophilic uorine sources, Selectuor or NFSI, 13 we were surprised to nd that 18 F labeled leucine or valine analogs have never been reported, apparently due to the synthetic inaccessibility of their corresponding precursors. Gratifyingly, subjection of the protected analogues of these two amino acids to our standard labeling conditions afforded exclusively tertiary carbon-labeled compounds 21 and 22 with RCCs of 29% and 31%, respectively. Tertiary selectively was also observed for the labeling of a leucine containing dipeptide complex, Boc-ValLeu-OMe, 23. In addition, 18 F labeled tyrosine analogs, such
, are also promising tracers for brain imaging.
14 Under our standard labeling reaction, a cyclopentane carboxylic ester derivative of tyrosine afforded the aliphatic ring labeled product 24 with an RCC of 40%. We anticipate that these compounds could have potential as tracers for amino acid transporter imaging. Another important application of PET imaging is in the area of pharmacokinetics as a noninvasive method for determining drug distribution and action. 15 Thus, an efficient method for introducing 18 F on a pre-existing drug motif may prove very useful in medicinal chemistry. In this context, several important drug molecules have been subjected to our standard labeling conditions. Radiolabeling of pregabalin, an anticonvulsant drug that has been commercialized by Pzer under the trade name Lyrica, 16 afforded mainly tertiary-labeled product 25. Analogs of utamide, 17 a prostate cancer drug, and ezetimibe, a cholesterol lowering drug, were both labeled efficiently at the tertiary positions, producing 27 and 28. Radio-uorination of amantadine, an antiviral and anti-Parkinson disease drug, afforded mostly the tertiary product 26 with secondary labeled compounds as minor side products, which were easily separated by semi-preparative HPLC. The separation of these regioisomers offers the potential for rapid testing of imaging properties of labeled analogs from a single late-stage synthetic product.
Finally, we have successfully translated this 18 F-labeling reaction into a reliable and reproducible protocol that can afford radiolabeled molecules on a scale suitable for animal studies. The scale up of the labeling reaction was achieved by with an overall 60% non-decay-corrected radio chemical yield (Scheme 3 and ESI † for details).
Conclusions
We have developed a direct aliphatic C-H 18 F labeling method using non-carrier-added [ 18 F]uoride that is suitable for inaccessible and unreactive sites. The value of this transformation has been highlighted via the radio-uorination of biologically active molecules without the need for pre-activation. Our future investigation will focus on developing PET tracers using this methodology and applying them for animal and human studies.
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